A key challenge in preclinical obesity, dysmetabolism, and diabetes studies is the lack of translational platforms that model the various aspects of disease progression and associated complications. Conventional rodent models of obesity do not recapitulate human disease, with more translational models required.
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about:
- Using translational rodent and non-human primate models to study obesity, dysmetabolism, diabetes, and related complications
- Exploiting the advantages of next generation rodent (FATZO mouse and ZDSD rat) and spontaneously diabetic non-human primate (NHP) models
- Modeling human-relevant disease progression and complications related to obesity and diabetes, including NAFLD/NASH, cardiac dysfunction, and nephropathy in translational rodents and NHPs
- Utilizing these translational models to assess the efficacy and safety of anti-diabetes and NAFLD/NASH therapeutics
